Picture of CONCORD DRUGS logo

538965 CONCORD DRUGS Share Price

0.000.00%
in flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Momentum

Relative Strength (%)
1m+3.09%
3m+13.91%
6m+1.92%
1yr+5.26%
Volume Change (%)
10d/3m-60.89%
Price vs... (%)
52w High-21.85%
50d MA-0.34%
200d MA+10.87%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital6.72%
Return on Equity2.89%
Operating Margin4.1%

Financial Summary

Year End 31st MarUnit201820192020202120222023E2024ECAGR / Avg
Total RevenueIN₹m517.97480.77513.39513.57589.56n/an/a0.51%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%+87.28+25.53-27.47+23.16+294.33n/an/an/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 202331st Mar 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of CONCORD DRUGS EPS forecast chart

Profile Summary

Concord Drugs Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing of licensed drugs based on the formulations approved. The Company offers finished pharmaceutical formulations, such as injectables (small volume parenteral, dry powders), tissue bio-adhesive, tablets, capsules, liquid orals (syrup & suspension) and dry syrups (powder). The Company also provides ready-to-fill pellets and multiple unit pellets system (MUPS). Its pellets are categorized as gastrointestinal drug pellets, cardiovascular drug pellets, respiratory drug pellets, anti-obesity drug pellets, anti-depressant drug pellets, central nervous system drug pellets, urological drug pellets, anti-microbial, anti-infective and adjuvant drugs pellets, taste mask drug pellets/powder, nutrition and food supplement drug pellets, anti cholesterol drug pellets. It also provides Iso Amyl 2-Cyano Acrylate, which is a bio-adhesive product.

Directors

Last Annual
March 31st, 2022
Last Interim
September 30th, 2022
Incorporated
January 24th, 1995
Public Since
February 23rd, 2015
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
in flag iconBombay Stock Exchange
Shares in Issue
8,743,750
Blurred out image of a map
Address
H.No.3-11-1/1A, HYDERABAD, 501511
Web
Phone
+91 4024037763
Auditors
N G Rao & Associates

538965 Share Price Performance

Upcoming Events for 538965

Similar to 538965

Picture of Achyut Healthcare logo

Achyut Healthcare

in flag iconBombay Stock Exchange

Picture of Adline Chem Lab logo

Adline Chem Lab

in flag iconBombay Stock Exchange

Picture of Advik Laboratories logo

Advik Laboratories

in flag iconBombay Stock Exchange

Picture of Albert David logo

Albert David

in flag iconBombay Stock Exchange

Picture of Ambalal Sarabhai Enterprises logo

Ambalal Sarabhai Enterprises

in flag iconBombay Stock Exchange

FAQ

Or unlock with your email

Or unlock with your email